KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

NovoCure (NVCR) Operating Income (2016 - 2026)

NovoCure's Operating Income history spans 13 years, with the latest figure at -$67.4 million for Q1 2026.

  • On a quarterly basis, Operating Income fell 78.05% to -$67.4 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$183.4 million, a 9.9% decrease, with the full-year FY2025 number at -$153.8 million, up 9.79% from a year prior.
  • Operating Income hit -$67.4 million in Q1 2026 for NovoCure, down from -$40.4 million in the prior quarter.
  • Over the last five years, Operating Income for NVCR hit a ceiling of -$806000.0 in Q1 2022 and a floor of -$67.4 million in Q1 2026.
  • Historically, Operating Income has averaged -$42.0 million across 5 years, with a median of -$40.4 million in 2025.
  • Biggest five-year swings in Operating Income: plummeted 7375.06% in 2023 and later surged 46.41% in 2024.
  • Tracing NVCR's Operating Income over 5 years: stood at -$43.0 million in 2022, then dropped by 20.33% to -$51.7 million in 2023, then dropped by 22.41% to -$63.3 million in 2024, then skyrocketed by 36.19% to -$40.4 million in 2025, then plummeted by 66.91% to -$67.4 million in 2026.
  • Business Quant data shows Operating Income for NVCR at -$67.4 million in Q1 2026, -$40.4 million in Q4 2025, and -$36.0 million in Q3 2025.